Shots:

• The companies collaborated to evaluate the combination of Gilead’s Trodelvy (Trop-2 targeting ADC) + Merck’s Keytruda (anti-PD-1 therapy) in a P-III trial in patients with metastatic NSCLC
• Merck will sponsor a global P-III clinical trial of Trodelvy + Keytruda as a 1L treatment for patients with metastatic NSCLC. Gilead will sponsor a P-II signal-seeking study to evaluate the combinations including pembrolizumab in 1L NSCLC
• Following the collaboration agreement with Gilead, Everest Medicines will also take part in the P-III study in Asia. Trodelvy is being used in metastatic TNBC & UC and is also being developed for HR+/HER2-metastatic breast cancer and metastatic NSCLC

Ref: Gilead | Image: Gilead